Compare Mesoblast Limited (MESO) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs J M Smucker Co — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while J M Smucker Co trades at $119.83 (market cap $12.76B). The key difference: J M Smucker Co is far larger — about 7.3× Mesoblast Limited's market cap, and J M Smucker Co pays a 3.75% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and J M Smucker Co for 74 Days on average.
| MESO | SJM | |
|---|---|---|
Market Cap | $1.75B | $12.76B |
Volume | 239,027 | 1,300,545 |
Sector | Health | Consumer Staples |
52-Week High | $20.96 | $132.34 |
52-Week Low | $13.19 | $89.53 |
Typical Hold Time | 15 Days | 74 Days |
Enterprise Value | $1.83B | $19.61B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
SJM trades at $119.83, up 3.36% today, with a bullish technical signal and recent earnings beats. The company reported strong Q2 2026 EPS of $3.24 versus $2.22 expected, though 2025 net income was negative $1.23B. Valuation ratios include a P/E of 55.8 and P/S of 1.39, with analyst consensus price target at $138.23.
Outlook is positive with raised 2027 guidance, but risks include volatile profitability and high debt. The stock offers a dividend yield from the upcoming $1.12 payment, supported by institutional buying. Earnings momentum and brand strength provide upside, yet margin pressures and competitive threats remain key watchpoints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
